A federal appeals court said the U.S. government was right to challenge Illumina’s purchase of cancer-test developer Grail, but still sent the case back to the Federal Trade Commission for reconsideration, The Wall Street Journal’s Dave Michaels reports. A three-judge panel found the deal to be anticompetitive, but said the FTC erred in how it considered Illumina’s proposed fix for its drawbacks. The judges ordered the FTC to reconsider its opinion on the troubled deal, which the European Commission has already ordered Illumina to unwind, the author notes.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ILMN:
- GE upgraded, Northrop Grumman downgraded: Wall Street’s top analyst calls
- Illumina just upgraded at Bernstein, here’s why
- Illumina upgraded to Market Perform from Underperform at Bernstein
- Foot Locker upgraded, Deckers downgraded: Wall Street’s top analyst calls
- Illumina initiated with bullish view at Guggenheim, here’s why